StreetAlpha.app
Home › Stocks › RPRX

Royalty Pharma plc (RPRX)

Healthcare
$68.45
▲ +1.08%
LAST CLOSE · NOV 20

Royalty Pharma buys royalty rights on biopharmaceutical medicines and receives payments tied to those drugs' sales. It last closed at $68.45 on Nov 20, up 1.08% on the day. The next earnings report for RPRX is expected around Wed, Feb 10, 2027. For the quarter ended Sep 2026, RPRX reported EPS of $0.32 on revenue of $690.1M, with revenue up 13.3% from a year ago. Over its last 8 reports the stock moved an average of 1.8% the session after earnings. Over the last 12 months RPRX insiders bought $0 of stock on the open market and sold $111.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is RPRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RPRX.

Key Stats

Last 12 months
Results
Revenue
$2.6B
+11.4% vs a year ago
Net income
$672.5M
−12.0% vs a year ago
EPS (diluted)
$1.53
−12.6% vs a year ago
Operating margin
57.1%
$1.5B operating income
Balance sheet
Cash & equivalents
$513.7M
At Sep 30
Debt
$8.6B
At Sep 30
Buybacks
$261.6M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.3B$2.3BFY2021FY2022: $2.2B$2.2BFY2022FY2023: $2.4B$2.4BFY2023FY2024: $2.3B$2.3BFY2024FY2025: $2.4B$2.4BFY2025

From RPRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 10
Estimated date · Time not announced
Reported EPS
$0.32
Quarter ended Sep 2026
Year ago EPS
$0.66
−51.5% on a GAAP basis
Revenue
$690.1M
+13.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.47Dec '24Mar 2025: $0.55Mar '25Jun 2025: $0.07Jun '25Sep 2025: $0.66Sep '25Dec 2025: $0.50Dec '25Mar 2026: $0.67Mar '26Jun 2026: $0.04Jun '26Sep 2026: $0.32Sep '26Latest $0.32
Revenue by quarter
Dec 2024: $593.6MDec '24Mar 2025: $568.2MMar '25Jun 2025: $578.7MJun '25Sep 2025: $609.3MSep '25Dec 2025: $622.0MDec '25Mar 2026: $630.6MMar '26Jun 2026: $674.1MJun '26Sep 2026: $690.1MSep '26Latest $690.1M
How RPRX moved after its last 8 reports
Average move the session after a report ±1.8%
Nov 4, 2026Time not announced+1.8%
Aug 5, 2026Time not announced+0.5%
May 6, 2026Time not announced+0.6%
Feb 11, 2026Time not announced+0.1%
Nov 5, 2025Time not announced+6.8%
Aug 6, 2025Time not announced−2.1%
May 8, 2025Time not announced+1.1%
Feb 11, 2025Time not announced+1.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RPRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RPRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RPRX

Technical Analysis

RPRX · as of the Nov 20 close · updated each morning
Uptrend, nearing overbought

The stock is 1% above its 20 day and 9% above its 50 day average. It is 19% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 63), near overbought. The nearest support is the Pivot at $68.41, and the nearest resistance the Pivot R1 at $68.87.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNear overbought
VolatilityNormal, 2.2%/day
Key levels
$70.3752 week high+2.8%
$69.77Swing high (Nov 5)+1.9%
$68.87Pivot R1+0.6%
$68.45Last close
$68.41Pivot−0.1%
$67.99Pivot S1−0.7%
$67.5920 day average−1.3%
$64.84Swing low (Nov 4)−5.3%
$62.3150 day average−9.0%
$60.76100 day average−11.2%
$55.26200 day average−19.3%
$37.3152 week low−45.5%
Indicators
RSI (14)63.30Strong, overbought above 70Neutral
MACD1.82Below its signal lineBearish
Stochastic62.2Middle of its rangeNeutral
ADX (14)35.6Trending up
Williams %R-34.7Oversold below −80, overbought above −20Neutral
CCI (20)43.9Oversold below −100, overbought above 100Neutral
Rate of change+1.7%Change over 10 sessionsBullish
ATR (14)$1.49Typical daily range, 2.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RPRX

What happened before

See how RPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RPRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RPRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RPRXHow many large options trades hit RPRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RPRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲388 buying vs 266 selling
  • ▲Shares held by funds +2.2%
  • ▲Funds holding +61
  • ▲Superinvestors: 4 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding707646+9.4%
In funds' top 101714+21.4%
Held by funds–––
New / increased111 / 27797 / 293−0.5%
Reduced / sold out218 / 48175 / 45+20.9%
Put/call ratio68.000.06+110961.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RPRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RPRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$111.1M39 sales · 5 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $19.7M2026-01 sold $9.4M2026-02 sold $11.9M2026-03 sold $3.2M2026-04 sold $3.4M2026-05 sold $5.1M2026-06 sold $16.0M2026-07 sold $508K2026-08 sold $6.6M2026-09 sold $6.1M2026-10 sold $236K2026-11 sold $26.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Christopher HiteEVP & Chairman, PartneringSale plan100,000$68.15$6.8M
Nov 17Terrance P. CoyneEVP & CFOSale plan257,122$68.81$17.7M
Nov 16Marshall UristEVP, Research & InvestmentsSale plan25,000$69.50$1.7M
Oct 5Marshall UristEVP, Research & InvestmentsSale plan4,126$57.10$236K
Sep 28Marshall UristEVP, Research & InvestmentsSale plan4,126$57.88$239K
Sep 22Christopher HiteEVP & Chairman, PartneringSale plan100,000$58.53$5.9M
Every insider buy and sale for RPRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RPRX insider trades →

From SEC Form 4 filings by RPRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RPRX is in one of them and how their past RPRX trades turned out.

RPRX in the AI portfolios
Loading…

RPRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RPRX in an article yet. Here's the latest on the wider market.

RPRX in the news

About Royalty Pharma

Royalty Pharma buys royalty rights on biopharmaceutical medicines, so it receives payments based on the sales of those drugs. It is based in New York. Its portfolio covers more than 35 marketed therapies across areas such as rare diseases, neuroscience, oncology, immunology and diabetes, along with some development-stage product candidates. Its customers are drug developers, from small and midsize biotechnology companies and academic or research institutions to large global pharmaceutical companies that sell the medicines.

Headquarters
New York, NY